Frazier Life Sciences Management, L.P. Portfolio Holdings

Frazier Life Sciences Management, L.P.

  • $1.59 Billion
  • Q1 2025

Frazier Life Sciences Management, L.P. has filed its 13F form on May 15, 2025 for Q1 2025 where it was disclosed a total value porftolio of $1.59 Billion distributed in 47 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Mirum Pharmaceuticals, Inc. with a value of $306M, Verona Pharma PLC with a value of $220M, Arcutis Biotherapeutics, Inc. with a value of $137M, Bridge Bio Pharma, Inc. with a value of $131M, and Krystal Biotech, Inc. with a value of $124M.

Examining the 13F form we can see an decrease of $78.6M in the current position value, from $1.67B to 1.59B.

Frazier Life Sciences Management, L.P. is based out at Menlo Park, CA

Below you can find more details about Frazier Life Sciences Management, L.P. portfolio as well as his latest detailed transactions.

Portfolio value $1.59 Billion
Healthcare: $1.59 Billion

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$1.91B
$306 Million 19.27% of portfolio
6,795,121
Q1 2025 Added 3.42%
$6.42B
$220 Million 13.82% of portfolio
3,457,850
Q1 2025 Added 2.18%
$923M
$137 Million 8.65% of portfolio
8,785,284
Q1 2024 Added 0.24%
$7.3B
$131 Million 8.27% of portfolio
3,800,457
Q4 2024 Added 1.06%
$3.52B
$124 Million 7.81% of portfolio
688,460
Q1 2025 Reduced 12.68%
$1.1B
$71.8 Million 4.52% of portfolio
1,397,527
Q1 2025 Reduced 11.97%
$433M
$64.5 Million 4.06% of portfolio
10,259,409
Q1 2025 Reduced 3.8%
$328M
$63.4 Million 3.99% of portfolio
10,109,279
Q2 2023 Added 20.25%
$321M
$56.4 Million 3.55% of portfolio
4,887,867
Q4 2024 Added 32.54%
$4.94B
$36 Million 2.26% of portfolio
678,760
Q1 2025 Reduced 63.7%
$3.37B
$35.3 Million 2.22% of portfolio
997,455
Q3 2023 Added 16.73%
$293M
$31.8 Million 2.0% of portfolio
11,462,301
Q1 2025 Added 32.35%
$1.98B
$31.3 Million 1.97% of portfolio
1,069,854
Q1 2025 Added 0.01%
$183M
$30.9 Million 1.95% of portfolio
22,575,851
Q1 2025 Added 16.42%
$2.03B
$23.9 Million 1.5% of portfolio
658,715
Q4 2024 Added 3.94%
$10.4B
$20.8 Million 1.31% of portfolio
133,333
Q3 2024 New
$4.37B
$19.8 Million 1.25% of portfolio
601,129
Q4 2024 Added 4.34%
$209M
$17.6 Million 1.11% of portfolio
7,819,863
Q1 2025 Added 53.4%
$3.09B
$15.7 Million 0.99% of portfolio
373,100
Q2 2024 Reduced 50.02%
$1.99B
$15.5 Million 0.98% of portfolio
525,000
Q1 2025 New
$68.5M
$15.4 Million 0.97% of portfolio
10,617,062
Q2 2024 Added 8.54%
$542M
$15.1 Million 0.95% of portfolio
1,443,341
Q1 2025 New
$3.87B
$12.6 Million 0.8% of portfolio
350,000
Q1 2025 New
$1.43B
$8.94 Million 0.56% of portfolio
301,170
Q1 2025 Added 176.91%
$382M
$7.87 Million 0.5% of portfolio
1,410,193
Q1 2025 Reduced 63.73%
$3.83B
$7.81 Million 0.49% of portfolio
470,338
Q1 2024 Reduced 35.65%
$227M
$7.54 Million 0.47% of portfolio
1,953,547
Q4 2024 Added 3.22%
$230M
$7.2 Million 0.45% of portfolio
1,079,025
Q1 2025 Reduced 27.04%
$211M
$7.17 Million 0.45% of portfolio
4,623,324
Q1 2024 Added 23.39%
$161M
$5.65 Million 0.36% of portfolio
3,868,750
Q1 2025 Added 34.91%
$507M
$5.63 Million 0.35% of portfolio
1,247,911
Q1 2025 Reduced 41.9%
$747M
$5.61 Million 0.35% of portfolio
936,576
Q1 2024 Reduced 53.06%
$102M
$4.03 Million 0.25% of portfolio
3,175,665
Q4 2024 Added 5.48%
$201M
$3.24 Million 0.2% of portfolio
1,148,591
Q1 2024 Added 30.35%
$8.39M
$1.56 Million 0.1% of portfolio
5,993,579
Q3 2024 Added 102.58%
Cg Oncology Inc
-
$0 0.0% of portfolio
-
Q1 2024 New
Soleno Therapeutics Inc
-
$0 0.0% of portfolio
-
Q1 2025 Reduced 28.61%
Mbx Biosciences Inc
-
$0 0.0% of portfolio
-
Q3 2024 New
Disc Medicine Inc
-
$0 0.0% of portfolio
-
Q2 2024 Added 123.55%
Lexeo Therapeutics Inc
-
$0 0.0% of portfolio
-
Q4 2024 Reduced 23.61%
Palvella Therapeutics Inc Ne
-
$0 0.0% of portfolio
-
Q1 2025 Added 5.52%
Oruka Therapeutics Inc
-
$0 0.0% of portfolio
-
Q4 2024 Added 22.21%
-
$0 0.0% of portfolio
-
Q4 2022 New
-
$0 0.0% of portfolio
-
Q1 2025 Added 1.26%
Maze Therapeutics Inc
-
$0 0.0% of portfolio
-
Q1 2025 New
Adverum Biotechnologies Inc
-
$0 0.0% of portfolio
-
Q2 2024 New

Summary

  • Portfolio
  • No. of Stocks 47
  • Current Value $1.59 Billion
  • Prior Value $1.67 Billion
  • Filing
  • Period Q1 2025
  • Filing Date May 15, 2025
  • Form Type 13F-HR
  • Activity in Q1 2025
  • New Purchases 4 stocks
  • Additional Purchases 10 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 8 stocks
Track This Portfolio

Track Frazier Life Sciences Management, L.P. Portfolio

Follow Frazier Life Sciences Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Frazier Life Sciences Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Frazier Life Sciences Management, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email